Valuation : FibroBiologics, Inc.

Market Cap 12.05M 10.36M 9.75M 8.9M 16.64M 1.14B 16.7M 116M 44.68M 584M 45.26M 44.27M 1.86B P/E 2026 *
-0.6x
P/E 2027 * -1.03x
Enterprise Value 12.05M 10.36M 9.75M 8.9M 16.64M 1.14B 16.7M 116M 44.68M 584M 45.26M 44.27M 1.86B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.13%
Yield 2026 *
-
Yield 2027 * -
1 day+2.84%
1 week+5.23%
Current month+5.23%
1 month+85.41%
3 months+75.73%
6 months-79.20%
Current year-59.76%
1 week 1.7
Extreme 1.7
2.18
1 month 0.95
Extreme 0.95
2.2
Current year 0.62
Extreme 0.62005
9.6
1 year 0.62
Extreme 0.62005
12.4
3 years 0.62
Extreme 0.62005
1,100
5 years 0.62
Extreme 0.62005
1,100
10 years 0.62
Extreme 0.62005
1,100
Manager TitleAgeSince
Chief Executive Officer 62 2021-04-07
Director of Finance/CFO 53 2025-06-08
Chief Tech/Sci/R&D Officer 57 2021-07-31
Director TitleAgeSince
Director/Board Member 60 2021-04-07
Chairman 62 2021-04-07
Director/Board Member 67 2021-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Other

Director

562 0.0108%
5/4/26 Free

Chief Executive Officer

92,410 2.6306%
5/4/26 Free

Chief Financial Officer

61,607 1.7538%
Change 5-day change 1-year change 3-year change Capi.($)
+2.84%+5.23%-84.24% - 12.05M
-0.38%-0.99%+42.69%+100.85% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-0.33%-2.26%+24.06%+13.26% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-5.02%+219.82%+379.02% 17.16B
-1.26%-1.31%-8.19%+518.95% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.15%+3.46%+28.74%+178.29% 27.91B
Weighted average by Cap. -0.79%+0.47%+36.56%+139.05%

Financials

2026 *2027 *
Net sales - -
Net income -18.51M -15.92M -14.97M -13.67M -25.56M -1.75B -25.64M -178M -68.61M -896M -69.51M -67.99M -2.86B -22.96M -19.74M -18.57M -16.95M -31.7M -2.17B -31.81M -220M -85.11M -1.11B -86.22M -84.33M -3.54B
Net Debt - -
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).
Employees
-
Date Price Change Volume
26-09-04 US$1.810 +2.84% 210,456
26-09-03 US$1.760 -9.74% 366,002
26-09-02 US$1.950 -7.58% 639,026
26-09-01 US$2.110 +22.67% 1,545,221
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.810USD
Average target price
12.50USD
Spread / Average Target
+590.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBLG Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!